Turning research into hope, connecting you to possibilities
Navigating cancer treatment options can be challenging—but it doesn’t have to be, our clinical research center provides a seamless way for patients, caregivers, and healthcare providers to explore ongoing cancer clinical trials, understand your options and take a step toward potentially life-saving advancements in care.
Every clinical trial is a step towards progress, and by exploring these opportunities, you’re not only seeking care but you’re also contributing to the future of cancer treatment. Help us make a difference.

About this study
- Last updated on
This study is for people with:
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Sponsored by:
Jazz Pharmaceuticals Ireland Limited
Number of participants
286 participants
Unique study ID
CTRI/2022/05/042831
Participation requirements
Inclusion Criteria
- Histologically- or cytologically-confirmed BTC, including GBC, ICC, or ECC.
- Locally advanced unresectable or metastatic BTC and not eligible for curative resection, transplantation, or ablative therapies.
- Received no more than 2 cycles of systemic therapy with gemcitabine and a platinum agent (eg, CisGem or GEMOX) with or without a PD-1/L1 inhibitor (physician’s choice of durvalumab or pembrolizumab, where approved under local regulations) for advanced unresectable or metastatic disease. Participants who have received prior adjuvant or neoadjuvant treatment (including investigational products) for earlier stage disease are permitted as long as therapy was completed more than 6 months prior to expected date of C1D1.
- HER2-positive disease (defined as IHC 3+; or IHC 2+/ ISH+) by IHC and ISH assay (in participants with IHC 2+ tumors) at a central laboratory on new biopsy tissue or archival tissue from the most recent biopsy (see Section 7.1). Note that fine needle aspirates (FNAs; cytology samples) and biopsies from sites of bone metastases are not acceptable. Testing may occur with tissue obtained at any time after diagnosis of BTC and before expected date of randomization.
a. When the central laboratory is available, samples must be sent to the central laboratory prior to randomization for determination of HER2 status. If it has been confirmed with the medical monitor that a central laboratory is not available, sites may use local testing for HER2 to enroll participants with IHC 3+ tumors. In this case, samples still must be sent to the central laboratory for confirmatory analyses once the central laboratory becomes available. - Assessable (measurable or non-measurable) disease as defined by RECIST 1.1, per investigator assessment.
- Male or female ≥ 18 years or age (or the legal age of adulthood per country-specific regulations).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate hematologic function as follows:
a. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L
b. Platelet count ≥ 100 × 109/L, not requiring transfusion support
c. Hemoglobin (Hgb) ≥ 9 g/dL (participants with chronic anemia that is supported by intermittent red blood cell transfusions are eligible) - Adequate hepatic function, as defined by both:
a. Aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN), and alanine aminotransferase (ALT) ≤ 3 × ULN. For participants with liver involvement, AST and ALT ≤ 5 × ULN is acceptable.
b. Total bilirubin ≤ 1.5 × ULN, or ≤ 3 × ULN for participants with Gilbert’s disease - Adequate renal function, as defined by estimated glomerular filtration rate (GFR) > 50 mL/min per local institutional standard method.
- Left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram or multiple gated acquisition scan (MUGA)
Exclusion Criteria
- Prior treatment with a HER2-targeted agent, with the exception of participants who completed HER2-targeted treatment for breast cancer > 5 years prior to their diagnosis of BTC.
- Prior treatment with checkpoint inhibitors, other than durvalumab or pembrolizumab as part of the up to 2 cycles of systemic therapy allowed prior to expected date of C1D1 per Inclusion Criterion 3. Exclusionary checkpoint inhibitors include but are not limited to other anti-PD-1, anti-PD-L1, anti-cytotoxic T lymphocyte-associated antigen (CTLA)-4 antibodies.
- The following BTC histologic subtypes are excluded: small cell cancer, neuroendocrine tumors, lymphoma, sarcoma, mixed tumor histology, and mucinous cystic neoplasms detected in the biliary tract region.
- Received radiotherapy within 2 weeks of expected date of C1D1.
- Had major surgery within 4 weeks of expected date of C1D1.
- Total lifetime load of anthracycline exceeding 360 mg/m2 doxorubicin or equivalent.
- Use of systemic corticosteroids administered at doses equivalent to > 10 mg per day of prednisone within 2 weeks of expected date of C1D1. Topical, ocular, intra-articular, intranasal, and/or inhalation corticosteroids are permitted.
- Brain metastases: Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks of expected date of C1D1. Stable, treated brain metastases are allowed (defined as participants who are off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks at the time of screening).
There are 9 locations for this study
How to apply
Fill the below form and our team will get in touch soon